Diagnosis and individualized therapy of neoplastic meningitis

Expert Review of Anticancer Therapy

Volumn 10, Issue 7, 2010, Pages 1137-1148

  Strik, Herwig ^a   Prömmel, Peter ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Ara C; capecitabine; cerebrospinal fluid cytology; CSF flow block; cytarabinoside; dacarbazine; dexamethasone; gemcitabine; intrathecal chemotherapy; liposomally encapsulated Ara C; meningeal carcinomatosis; methotrexate; neoplastic meningitis; rituximab; temozolomide; thiotepa; topotecan; trastuzumab; vincristine

Indexed keywords

CAPECITABINE; CYTARABINE; DEXAMETHASONE; GEMCITABINE; LIPOSOME; METHOTREXATE; MOLECULAR MARKER; RITUXIMAB; TEMOZOLOMIDE; TOPOTECAN; TRASTUZUMAB; VINCRISTINE; ANTINEOPLASTIC AGENT;

BACKACHE; BLURRED VISION; CANCER CHEMOTHERAPY; CEREBROSPINAL FLUID CYTOLOGY; CONTRAST ENHANCEMENT; CRANIAL NERVE PARALYSIS; DIPLOPIA; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; EPIDEMIOLOGICAL DATA; EPILEPSY; FACIAL NERVE PARALYSIS; HUMAN; IMMUNOCYTOCHEMISTRY; MENINGEAL BIOPSY; MENINGEAL METASTASIS; MENINGITIS; MENTAL DISEASE; MULTIMODALITY CANCER THERAPY; NEOPLASTIC MENINGITIS; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PROCESSING; PROTEIN CEREBROSPINAL FLUID LEVEL; REVIEW; VOMITING; ADULT; CARCINOMA; CEREBROSPINAL FLUID; CYTOLOGY; DIAGNOSTIC IMAGING; FEMALE; INTRASPINAL DRUG ADMINISTRATION; MALE; MENINX; MIDDLE AGED; NERVOUS SYSTEM DISEASES; PATHOLOGY; PERSONALIZED MEDICINE; SKULL IRRADIATION; TUMOR INVASION;

ADULT; ANTINEOPLASTIC AGENTS; CARCINOMA; CEREBROSPINAL FLUID; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; CYTARABINE; DIAGNOSTIC IMAGING; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; INJECTIONS, SPINAL; LIPOSOMES; MAGNETIC RESONANCE IMAGING; MALE; MENINGES; MENINGITIS; MIDDLE AGED; NEOPLASM INVASIVENESS; NERVOUS SYSTEM DISEASES;

EID: 77954884383     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.86     Document Type: Review

References (63)

1. Weller M, Bamberg M, Engenhart- Cabillic R et al. Spinale metastasen und meningeosis neoplastica. In: Leitlinien fur Diagnostik und Therapie in der Neurologie. Diener HC, Putzki N (Eds). Thieme, Stuttgart, Germany, 797-802 (2008).
2. Glass JP, Melamed M, Chernik NL et al. Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology 29, 1369-1375 (1979).
3. Posner JB, Chernik NL. Intracranial metastases from systemic cancer. Adv. Neurol. 19, 579-592 (1978).
4. Chamberlain MC. Neoplastic meningitis. J. Clin. Oncol. 23, 3605-3613 (2005).
5. DeAngelis LM, Boutros D. Leptomeningeal metastasis. Cancer Invest. 23, 145-154 (2005).
6. Pavlidis N. The diagnostic and therapeutic management of leptomeningeal carcinomatosis. Ann. Oncol. 15(Suppl. 4), IV285-IV291 (2004).
7. Gleissner B, Hoelzer D, Thiel E. Therapie der Meningeosis Neoplastica. Onkologie 40-45 (2005).
8. Herman TS, Hammond N, Jones SE et al. Involvement of the central nervous system by non-Hodgkin's lymphoma: the Southwest Oncology Group experience. Cancer 43, 390-397 (1979).
9. Wolk RW, Masse SR, Conklin R et al. The incidence of central nervous system leukemia in adults with acute leukemia. Cancer 33, 863-869 (1974).
10. Gokbuget N, Hoelzer D. Meningeosis leukaemica in adult acute lymphoblastic leukaemia. J. Neurooncol. 38, 167-180 (1998).
11. Stewart DJ, Keating MJ, McCredie KB et al. Natural history of central nervous system acute leukemia in adults. Cancer 47, 184-196 (1981).
12. Strik HM, Effenberger O, Schafer O et al. A case of spinal glioblastoma multiforme: immunohistochemical study and review of the literature. J. Neurooncol. 50, 239-243 (2000).
13. Chamberlain MC. Neoplastic meningitis. Semin. Neurol. 24, 363-374 (2004).
14. Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 49, 759-772 (1982).
15. Balm M, Hammack J. Leptomeningeal carcinomatosis. Presenting features and prognostic factors. Arch. Neurol. 53, 626-632 (1996).
16. Olson ME, Chernik NL, Posner JB. Infiltration of the leptomeninges by systemic cancer. A clinical and pathologic study. Arch. Neurol. 30, 122-137 (1974).
17. Herrlinger U, Astner S, Thiel E. Meningeosis neoplastica im Rahmen einer ZNS-Metastasierung. Der Onkologe 14, 267-273 (2008).
18. Crivellari D, Pagani O, Veronesi A et al. High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Ann. Oncol. 12, 353-356 (2001).
19. Bendell JC, Domchek SM, Burstein HJ et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97, 2972-2977 (2003).
20. Menger H, Lincke HO, Remmers J. Verlauf der meningealen tumoraussaat - analyse von 85 patienten. Aktuelle Neurologie 20, 196-202 (1993).
21. Chamberlain MC, Kormanik PA. Prognostic significance of mindium-DTPA CSF flow studies in leptomeningeal metastases. Neurology 46, 1674-1677 (1996).
22. Sze G, Soletsky S, Bronen R et al. MR imaging of the cranial meninges with emphasis on contrast enhancement and meningeal carcinomatosis. AJR Am. J. Roentgenol. 153, 1039-1049 (1989). (Pubitemid 19269378)
23. Freilich RJ, Krol G, DeAngelis LM. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann. Neurol. 38, 51-57 (1995).
24. Zeiser R, Burger JA, Bley TA et al. Clinical follow-up indicates differential accuracy of magnetic resonance imaging and immunocytology of the cerebral spinal fluid for the diagnosis of neoplastic meningitis - a single centre experience. Br. J. Haematol. 124, 762-768 (2004).
25. Strik HM, Proemmel P, Pilgram-Pastor S, Buhk JH. Neoplastic meningitis - is MRI as sensitive as CSF cytology? J. Clin. Oncol. 27 (2009) (Abstract 9566).
26. Fischer L, Martus P, Weller M et al. Meningeal dissemination in primary CNS lymphoma: prospective evaluation of 282 patients. Neurology 71, 1102-1108 (2008).
27. Kleyweg RP, Hertzberger LI, Carbaat PA. [Less headache following lumbar puncture with the use of an atraumatic needle; double-blind randomized study]. Ned. Tijdschr. Geneeskd. 139, 232-234 (1995).
28. Heller T, Nagel I, Ehrlich B et al. Automated cerebrospinal fluid cytology. Anal. Quant. Cytol. Histol. 30, 139-144 (2008).
29. Strik H, Luthe H, Nagel I et al. Automated cerebrospinal fluid cytology: limitations and reasonable applications. Anal. Quant. Cytol. Histol. 27, 167-173 (2005).
30. Zettl U, Mix E, Lehmitz R. Neoplastische erkrankungen des nervensystems: meningeosis neoplastica. In: Klinische Liquordiagnostik. Zettl U, Lehmitz R, Mix E (Eds). De Gruy ter, Berlin, Germany, 418-419 (2003).
31. Kleine TO. Liquordiagnostik. Methoden und klinische bedeutung. In: Klinische Liquordiagnostik. Zettl U, Lehmitz R, Mix E (Eds). De Gruyter, Berlin, Germany, 130-133 (2003).
32. Schipper HI, Bardosi A, Jacobi C et al. Meningeal carcinomatosis: origin of local IgG production in the CSF. Neurology 38, 413-416 (1988).
33. Proemmel P, Buhk J, Pilgram-Pastor S et al. Diagnostics of neoplastic meningitis - the value of MRI and patterns of lymphomatous cytomorphology. Oncology (2010) (Abstract PO0414) (In press).
34. Jacobi C, Reiber H, Felgenhauer K. The clinical relevance of locally produced carcinoembryonic antigen in cerebrospinal fluid. J. Neurol. 233, 358-361 (1986).
35. Almeida SM, Cunha DS, Yamada E, Doi EM, Ono M. Quantification of cerebrospinal fluid ferritin as a biomarker for CNS malignant infiltration. Arq. Neuropsiquiatr. 66, 720-724 (2008).
36. Hegde U, Filie A, Little RF et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood 105, 496-502
37. Baehring JM, Hochberg FH, Betensky RA, Longtine J, Sklar J. Immunoglobulin gene rearrangement analysis in cerebrospinal fluid of patients with lymphoproliferative processes. J. Neurol. Sci. 247, 208-216 (2006) .
38. Sayed D, Badrawy H, Ali AM, Shaker S. Immunophenotyping and immunoglobulin heavy chain gene rearrangement analysis in cerebrospinal fluid of pediatric patients with acute lymphoblastic leukemia. Leuk. Res. 33, 655-661 (2009).
39. Hug A, Storch-Hagenlocher B, Haas J, Vogt-Schaden ME, Goldschmidt H, Wildemann B. Single-cell PCR analysis of the immunoglobulin heavy-chain CDR3 region for the diagnosis of leptomeningeal involvement of B-cell malignancies using standard cerebrospinal fluid cytospins. J. Neurol. Sci. 219, 83-88 (2004).
40. van Oostenbrugge RJ, Hopman AH, Lenders MH et al. Detection of malignant cells in cerebrospinal fluid using fluorescence in situ hybridization. J. Neuropathol. Exp. Neurol. 56, 743-748 (1997).
41. DeAngelis LM. Current diagnosis and treatment of leptomeningeal metastasis. J. Neurooncol. 38, 245-252 (1998).
42. Grossman SA, Finkelstein DM, Ruckdeschel JC et al. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J. Clin. Oncol. 11, 561-569 (1993).
43. Bokstein F, Lossos A, Siegal T. Leptomeningeal metastases from solid tumors: a comparison of two prospective series treated with and without intra- cerebrospinal fluid chemotherapy. Cancer 82, 1756-1763 (1998).
44. Boogerd W, Hart AA, van der Sande JJ et al. Meningeal carcinomatosis in breast cancer. Prognostic factors and influence of treatment. Cancer 67, 1685-1695 (1991).
45. Fizazi K, Asselain B, Vincent-Salomon A et al. Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen. Cancer 77, 1315-1323 (1996).
46. Jenkin RD. Medulloblastoma in childhood: radiation therapy. Can. Med. Assoc. J. 100, 51-53 (1969).
47. Hughes EN, Shillito J, Sallan SE et al. Medulloblastoma at the joint center for radiation therapy between 1968 and 1984. The influence of radiation dose on the patterns of failure and survival. Cancer 61, 1992-1998 (1988).
48. Brandes AA, Franceschi E, Tosoni A et al. Adult neuroectodermal tumors of posterior fossa (medulloblastoma) and of supratentorial sites (stPNET). Crit. Rev. Oncol. Hematol. 71, 165-179 (2009).
49. Weller M, Schlegel U. Grundlagen der speziellen therapie: chemotherapie. In: Neuroonkologie. Schlegel U, Weller M, Westphal M (Eds.), Thieme, Stuttgart, Germany, 156-164 (2003).
50. Slyter H, Liwnicz B, Herrick MK et al. Fatal myeloencephalopathy caused by intrathecal vincristine. Neurology 30, 867-871 (1980).
51. Shepherd DA, Steuber CP, Starling KA et al. Accidental intrathecal administration of vincristine. Med. Pediatr. Oncol. 5, 85-88 (1978).
52. Stemmler HJ, Schmitt M, Harbeck N et al. Application of intrathecal trastuzumab (Herceptin) for treatment of meningeal carcinomatosis in HER2 overexpressing metastatic breast cancer. Oncol. Rep. 15, 1373-1377 (2006).
53. Rubenstein JL, Fridlyand J, Abrey L et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J. Clin. Oncol. 25, 1350-1356 (2007).
54. Liu CY, Teng HW, Lirng JF, Chiou TJ, Chen PM, Hsiao LT. Sustained remission and long-term survival of secondary central nervous system involvement by aggressive B-cell lymphoma after combination treatment of systemic high-dose chemotherapy and intrathecal rituximab. Leuk. Lymphoma 49, 2018-2021 (2008).
55. Jaime-Perez JC, Rodnguez-Romo LN, Gonzalez-Llano O, Chapa-Rodnguez A, Gomez-Almaguer D. Effectiveness of intrathecal rituximab in patients with acute lymphoblastic leukaemia relapsed to the CNS and resistant to conventional therapy. Br. J. Haematol. 144, 794-795 (2009).
56. Bleyer WA, Drake JC, Chabner BA. Neurotoxicity and elevated cerebrospinal- fluid methotrexate concentration in meningeal leukemia. N. Engl. J. Med. 289, 770-773 (1973).
57. Chamberlain MC, Khatibi S, Kim JC et al. Treatment of leptomeningeal metastasis with intraventricular administration of depot cytarabine (DTC 101). A Phase I study. Arch. Neurol. 50, 261-264 (1993).
58. Glantz MJ, LaFollette S, Jaeckle KA et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J. Clin. Oncol. 17, 3110-3116 (1999).
59. Glantz MJ, Jaeckle KA, Chamberlain MC et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin. Cancer Res. 5, 3394-3402 (1999).
60. Cole BF, Glantz MJ, Jaeckle KA et al. Quality-of-life-adjusted survival comparison of sustained-release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitis. Cancer 97, 3053-3060 (2003).
61. Glantz MJ, Van Horn A, Fisher R, Chamberlain MC. Route of intracerebrospinal fluid chemotherapy administration and efficacy of therapy in neoplastic meningitis. Cancer 116(8), 1947-1952 (2010).
62. Jabbour E, O'Brien S, Kantarjian H et al. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood 109, 3214-3218 (2007).
63. Nevinny-Stickel M, Stockhammer G, Muigg A, Posch A, Seppi T, Lukas P. Concomitant intrathecal liposomal cytarabine and radiotherapy: a new approach for treating combined parenchymal and leptomeningeal metastases. Onkologie 31(Suppl. 4), 215 (2008) (Abstract 625).